{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:54Z","timestamp":1791331254972,"version":"4.3.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/cco.0b013e32833d752c","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T03:07:06Z","timestamp":1280977626000},"page":"579-585","source":"Crossref","is-referenced-by-count":28,"title":["Recent advances of IMiDs in cancer therapy"],"prefix":"10.1097","volume":"22","author":[{"given":"Shirong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navkiranjit","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","article-title":"Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism","volume":"69","author":"Escoubet-Lozach","year":"2009","journal-title":"Cancer Res"},{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.4049\/jimmunol.0900476","article-title":"Thalidomide inhibits activation of caspase-1","volume":"183","author":"Keller","year":"2009","journal-title":"J Immunol"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2009-02-200543","article-title":"Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases","volume":"114","author":"Xu","year":"2009","journal-title":"Blood"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","article-title":"Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway","volume":"115","author":"Lapalombella","year":"2010","journal-title":"Blood"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"12974","DOI":"10.1073\/pnas.0811267106","article-title":"A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide","volume":"106","author":"Wei","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1182\/blood-2004-03-0828","article-title":"Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis","volume":"105","author":"Koh","year":"2005","journal-title":"Blood"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","article-title":"Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia","volume":"115","author":"Pal","year":"2010","journal-title":"Blood"},{"key":"R13-8-20210128","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3324\/haematol.2009.010876","article-title":"Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion","volume":"95","author":"Ximeri","year":"2010","journal-title":"Haematologica"},{"key":"R15-8-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14656560802627903","article-title":"Lenalidomide: a novel anticancer drug with multiple modalities","volume":"10","author":"Galustian","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R16-8-20210128","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anticancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"R18-8-20210128","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3324\/haematol.2009.005835","article-title":"Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia","volume":"94","author":"Aue","year":"2009","journal-title":"Haematologica"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/leu.2009.279","article-title":"Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients","volume":"24","author":"Chan","year":"2010","journal-title":"Leukemia"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2009.015495","article-title":"In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma","volume":"95","author":"Ocio","year":"2010","journal-title":"Haematologica"},{"key":"R21-8-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","article-title":"Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells","volume":"112","author":"Lapalombella","year":"2008","journal-title":"Blood"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.leukres.2008.06.001","article-title":"Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma","volume":"33","author":"van der Spek","year":"2009","journal-title":"Leuk Res"},{"key":"R24-8-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/10428190802588352","article-title":"Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1","volume":"50","author":"Liu","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R25-8-20210128","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.leukres.2008.09.018","article-title":"Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients","volume":"33","author":"Oliveira","year":"2009","journal-title":"Leuk Res"},{"key":"R27-8-20210128","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"R33-8-20210128","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","article-title":"Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)","volume":"113","author":"Knop","year":"2009","journal-title":"Blood"},{"key":"R34-8-20210128","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"key":"R36-8-20210128","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2008-08-175778","article-title":"Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study","volume":"113","author":"Ades","year":"2009","journal-title":"Blood"},{"key":"R37-8-20210128","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2009.26.0745","article-title":"Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes","volume":"28","author":"Sekeres","year":"2010","journal-title":"J Clin Oncol"},{"key":"R45-8-20210128","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"R48-8-20210128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"R50-8-20210128","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib- containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32833d752c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:32:36Z","timestamp":1786041156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201011000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32833d752c","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}